In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models

被引：101

作者：

Snyder, Christopher ^{[1
]}

Chollet, Jacques ^{[1
]}

Santo-Tomas, Josefina ^{[1
]}

Scheurer, Christian ^{[1
]}

Wittlin, Sergio ^{[1
]}

机构：

[1] Swiss Trop Inst, CH-4002 Basel, Switzerland

来源：

EXPERIMENTAL PARASITOLOGY | 2007年 / 115卷 / 03期

关键词：

malaria; Plasmodium falciparum; Plasmodium berghei; RBx11160 (OZ277); peroxide; piperaquine; in vitro and in vivo combinations;

D O I：

10.1016/j.exppara.2006.09.016

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

RBx 11160 (OZ277) is a promising antimalarial drug candidate that Ranbaxy Laboratories Limited and Medicines for Malaria Venture (MMV) are currently developing as a fixed combination with piperaquine. Here, we describe the in vitro (Plasmodium falcipartan) and in vivo (Plasmodium berghei) activities of piperaquine in combination with RBx11160 and artemether. In vitro, both combinations demonstrated a slight tendency towards antagonism with mean sums of fractional inhibitory concentrations (mean Sigma FICs) of 1.5. In vivo, piperaquine and artemether were borderline antagonistic (mean Sigma FIC of 1.4). However, an additive in vivo interaction of piperaquine and RBx11160 (mean Sigma FIC of 1.1) was identified, suggesting that a RBx11160-piperaquine combination therapy in humans should allow each molecule to exert its full antimalarial effect. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：296 / 300

页数：5

共 16 条

[1] INTERACTIONS OF ATOVAQUONE WITH OTHER ANTIMALARIAL-DRUGS AGAINST PLASMODIUM-FALCIPARUM IN-VITRO [J].